Intellia Therapeutics (NASDAQ:NTLA) executives outlined plans for a potential launch of its hereditary angioedema treatment, ...

Intellia Therapeutics NTLA leverages its proprietary technologies and expertise, including CRISPR-based gene-editing ...

Shares of Intellia Therapeutics (NASDAQ:NTLA) rose 6% after Citizens JMP Securities upgraded the stock from Market Perform to Market Outperform with a new $33 price target, citing a strengthened ...

News shared this week that Intellia Therapeutics, Inc.'s pivotal study of candidate lonvo-z is fully enrolled has been greeted warmly by the market, with good reason. NTLA stock remains a compelling ...

CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies ...

FDA sets Prescription Drug User Fee Act (PDUFA)date of March 10, 2027Positions lonvo-z to be the world’s first in vivo CRISPR-based therapy and ...

CAMBRIDGE, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...

In the preceding three months, 4 analysts have released ratings for Intellia Therapeutics (NASDAQ:NTLA), presenting a wide array of perspectives from bullish to bearish. In the table below, you'll ...

Intellia Therapeutics, Inc. will hold a conference call on February 27, 2025, at 8 a.m. ET to present its fourth quarter and full-year 2024 financial results and operational highlights. Participants ...

Intellia Therapeutics Says FDA Accepts Lonvo-z BLA for Hereditary Angioedema MT 09:26am Intellia Therapeutics Receives FDA Acceptance Of Biologics License Application With Priority Review For ...

Intellia Therapeutics, a biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and ...